Daniel Scolnick > Goodwin > Philadelphia, United States > Lawyer Profile
Goodwin Offices
![Goodwin company logo](https://www.legal500.com/wp-content/uploads/sites/13/2022/05/50382.jpg?v=1653298090)
One Commerce Square
2005 Market St, 32nd floor
Philadelphia, Pennsylvania
19103
United States
- Firm Profile
- Go to...
Daniel Scolnick
![Daniel Scolnick photo](https://www.legal500.com/wp-content/uploads/sites/13/2024/06/scolnick-daniel-377x270px-300x215.jpg)
Position
Partner
Career
Daniel M. Scolnick is a partner in the Life Sciences group at Goodwin. Dr. Scolnick concentrates his practice in intellectual property law, including strategic patent prosecution and counseling, licensing, developing therapeutic exclusivity strategies, due diligence, and other transactional support for pharmaceutical, biotech, life sciences, and chemical companies. He is a registered patent attorney and holds a PhD in Biochemistry and Biophysics. He joined Goodwin in 2023.
Dr. Scolnick’s clients include startup and midsize biotechnology and pharmaceutical companies, venture capital groups, and Fortune 500 companies. His clients turn to him for matters that arise in the development and marketing of products in all areas of life sciences, including therapeutic antibodies, protein therapeutics, cell and gene therapy, stem cells, CAR-T, small molecules, other biologics, diagnostics, and devices.
As a PhD candidate and a post-doctoral fellow at the University of Pennsylvania, Dr. Scolnick acquired extensive experience in biochemistry, molecular biology, cell-based technologies, viral vectors, protein chemistry, and genetics. As an undergraduate, Dr. Scholnick’s research concentrated on synthetic organic chemistry where he focused on defining the structure and function of anticonvulsants by synthesizing various compounds and having them tested in animal models. Dr. Scolnick’s experience also includes materials science work where he performed synthesis and analytical work at the University of Pennsylvania’s chemistry department as a summer fellow investigating the synthesis and purification techniques involving nanomaterials.
Dr. Scolnick has also authored eight peer-reviewed scientific articles including one that was published in the journal Nature that described the cloning and characterization of a novel cell cycle gene that has been subsequently found to be intricately involved in the progression of many cancers.
Education
JD 2008 Villanova University Charles Widger School of Law (magna cum laude, Order of the Coif); PhD Biochemistry and Biophysics 2000 University of Pennsylvania; BA Chemistry with a concentration in Biochemistry 1995 Washington University in St. Louis
Lawyer Rankings
United States > Intellectual property > Patents: prosecution (including re-examination and post-grant proceedings)
(Firms to watch)Goodwin‘s patent prosecution collective has been significantly bolstered with the arrivals of David Chen to Santa Monica in October 2023 from Ropes & Gray LLP and of Pittsburgh-based Alicia Palladino, Philadelphia’s Daniel Scolnick and Timothy Atkins from Troutman Pepper in February of the same year.
Lawyer Rankings
Top Tier Firm Rankings
- Finance > Financial services regulation
- Industry focus > Cannabis
- Intellectual property > Patents: licensing
- M&A/corporate and commercial > Private equity buyouts: middle-market (Up to $500m)
- Real estate > Real estate investment trusts (REITs)
- Media, technology and telecoms > Technology transactions
- M&A/corporate and commercial > Venture capital and emerging companies
Firm Rankings
- Finance > Capital markets: equity offerings
- Labor and employment > ERISA litigation
- Finance > Fintech
- Healthcare > Life sciences
- Dispute resolution > M&A litigation: defense
- M&A/corporate and commercial > M&A: middle-market ($500m-999m)
- Real estate > Real estate
- Dispute resolution > Securities litigation: defense
- Intellectual property > Trade secrets (litigation and non-contentious matters)
- Finance > Capital markets: debt offerings
- International trade > CFIUS
- M&A/corporate and commercial > Corporate governance
- Media, technology and telecoms > Cyber law (including data privacy and data protection)
- Dispute resolution > E-discovery
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Dispute resolution > Financial services litigation
- Antitrust > Merger control
- Intellectual property > Patents: litigation (full coverage)
- Investment fund formation and management > Private equity funds (including venture capital)
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Tax > US taxes: non-contentious
- Labor and employment > Workplace and employment counseling
- International trade > Customs, export controls and economic sanctions
- Healthcare > Service providers
- Dispute resolution > Leading trial lawyers
- Dispute resolution > Leading trial lawyers
- Finance > Restructuring (including bankruptcy): corporate
- Dispute resolution > Appellate: courts of appeals / Appellate: supreme courts (states and federal)
- Finance > Commercial lending
- Dispute resolution > Corporate investigations and white-collar criminal defense
- Intellectual property > Patents: prosecution (including re-examination and post-grant proceedings)
- Intellectual property > Patents: litigation (International Trade Commission)
- M&A/corporate and commercial > Shareholder activism